A. Executive Summary
B. Global Pharmaceutical Industry
B.1 Industry Definition
B.2 Industry Overview
B.3 Industry Value
B.4 Market Share Analysis
B.5 Industry Forecast
C. Analyzing the Pharmaceutical Industry in the US
C.1 Impact of COVID-19 on the Industry
C.2 Industry Statistics
C.3 Industry Growth by Value Analysis
C.4 Industry Segmentation
C.5 Market Share Analysis
C.6 Industry Forecast
D. US Pharmaceutical Industry – SWOT Framework Analysis
D.1 Strengths to Build Upon
D.2 Weaknesses to Overcome
D.3 Opportunities to Exploit
D.4 Threats to Overcome
E. Analyzing the US Generics Industry
E.1 Industry Definition
E.2 Industry Statistics
E.3 Industry Growth Analysis
E.4 Industry Forecast
F. Analyzing the US OTC Pharmaceutical Industry
F.1 Industry Definition
F.2 Industry Statistics
F.3 Industry Growth by Value Analysis
F.4 Industry Segmentation
F.5 Market Share Analysis
F.6 Industry Forecast
G. US Pharmaceutical Industry: Porter’s Five Forces Strategy Analysis
G.1 Bargaining Power of Buyers
G.2 Bargaining Power of Suppliers
G.3 Competitive Rivalry in the Industry
G.4 Threat of New Entrants
G.5 Threat of Substitutes
H. US Pharmaceutical Industry: PEST Framework Analysis
H.1 Political Features
H.2 Economic Aspects
H.3 Social Aspects
H.4 Technological Aspects
I. International Competition and Economic Trends in the US Pharma Industry
I.1 Overall Changes in the Industry
I.2 Consolidation
I.3 Modifications in Geographical Concentrations
I.4 Global Trade and Competition
J. Key Trends in the Pharmaceutical Sector Supply Chain
J.1 Restructuring of the Supply Chain
J.2 Decline of Market Share and Margins
J.3 Decreased Access to Newer Drugs
K. Market Trends & Challenges
L. Research and Development
L.1 Economics of Innovation
L.2 R&D Process
L.3 New Medicines under Development
L.4 Treatments for Rare Diseases
L.5 Case Study – Personalized Medicines
L.6 Patent Incentives & Cooperation in the Industry
M. Patents in the US Pharmaceutical Industry
M.1 Introduction
M.2 Hatch Waxman Provisions
M.3 Patent Protection Regime for Branded Drugs
M.3.1 How to Extend the Exclusivity
M.3.2 Limitations on Multiple 30 Month Stays
M.3.3 Medicare Amendments
M.3.4 Changes in the Medicare Rx Drug Improvement Act
M.4 Looking at Offensive Patenting
M.5 Defensive Patenting
M.6 Conclusion
N. Leading Players
N.1 Abbot Laboratories
N.1.1 Corporate Snapshot
N.1.2 Business Segment Analysis
N.1.3 Financial Analysis
N.1.4 SWOT Analysis
N.2 AbbVie Inc.
N.2.1 Corporate Snapshot
N.2.2 Business Segment Analysis
N.2.3 Financial Analysis
N.2.4 SWOT Analysis
N.3 Allergan
N.3.1 Corporate Snapshot
N.3.2 Business Segment Analysis
N.3.3 Financial Analysis
N.3.4 SWOT Analysis
N.4 Amgen
N.4.1 Corporate Snapshot
N.4.2 Business Segment Analysis
N.4.3 Financial Analysis
N.4.4 SWOT Analysis
N.5 Bristol Myers Squibb
N.5.1 Corporate Snapshot
N.5.2 Business Segment Analysis
N.5.3 Financial Analysis
N.5.4 SWOT Analysis
N.6 Eli Lilly and Company
N.6.1 Corporate Snapshot
N.6.2 Business Segment Analysis
N.6.3 Financial Analysis
N.6.4 SWOT Analysis
N.7 Gilead Sciences
N.7.1 Corporate Snapshot
N.7.2 Business Segment Analysis
N.7.3 Financial Analysis
N.7.4 SWOT Analysis
N.8 GlaxoSmithKline
N.8.1 Corporate Snapshot
N.8.2 Business Segment Analysis
N.8.3 Financial Analysis
N.8.4 SWOT Analysis
N.9 Johnson & Johnson
N.9.1 Corporate Snapshot
N.9.2 Business Segment Analysis
N.9.3 Financial Analysis
N.9.4 SWOT Analysis
N.10 Merck & Co., Inc.
N.10.1 Corporate Snapshot
N.10.2 Business Segment Analysis
N.10.3 Financial Analysis
N.10.4 SWOT Analysis
N.11 Pfizer Inc.
N.11.1 Corporate Snapshot
N.11.2 Business Segment Analysis
N.11.3 Financial Analysis
N.11.4 SWOT Analysis
N.12 Teva Pharmaceutical Industries Limited
N.12.1 Corporate Snapshot
N.12.2 Business Segment Analysis
N.12.3 Financial Analysis
N.12.4 SWOT Analysis
N. Glossary of Terms